Auris Medical (EARS) Issues Earnings Results, Misses Estimates By $0.01 EPS

Auris Medical (NASDAQ:EARS) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01), MarketWatch Earnings reports.

Shares of NASDAQ:EARS traded down $0.02 during trading on Friday, reaching $0.38. 33,055 shares of the company traded hands, compared to its average volume of 1,787,490. The firm has a market capitalization of $15.19 million, a P/E ratio of -0.07 and a beta of -0.56. Auris Medical has a 1-year low of $0.23 and a 1-year high of $3.08.

A number of equities analysts recently commented on EARS shares. Roth Capital started coverage on shares of Auris Medical in a research note on Thursday, December 20th. They issued a “buy” rating and a $5.00 price objective for the company. ValuEngine raised shares of Auris Medical from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, Zacks Investment Research lowered shares of Auris Medical from a “buy” rating to a “hold” rating in a research note on Monday, January 21st.

ILLEGAL ACTIVITY NOTICE: “Auris Medical (EARS) Issues Earnings Results, Misses Estimates By $0.01 EPS” was published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.thestockobserver.com/2019/03/15/auris-medical-ears-issues-earnings-results-misses-estimates-by-0-01-eps.html.

About Auris Medical

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.

Further Reading: What are no-load funds?

Earnings History for Auris Medical (NASDAQ:EARS)

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.